Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
8.02
+1.27 (18.81%)
At close: Mar 9, 2026, 4:00 PM EDT
8.07
+0.05 (0.62%)
After-hours: Mar 9, 2026, 5:13 PM EDT
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
624.84M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Fulcrum Therapeutics | 80.00M |
| ADC Therapeutics | 75.21M |
| Invivyd | 53.43M |
| Prothena Corporation | 9.68M |
| Ocugen | 4.41M |
| Allogene Therapeutics | 22.00K |
SLDB News
- 3 days ago - Solid Biosciences Announces Oversubscribed $240 Million Private Placement - GlobeNewsWire
- 3 days ago - Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewsWire
- 7 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 27 days ago - Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones - Seeking Alpha
- 4 weeks ago - Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - GlobeNewsWire
- 4 weeks ago - Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 7 weeks ago - Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha